February 5, 2018 / 12:40 PM / 19 days ago

BRIEF-Palatin Technologies Initiates Subject Dosing In First-In-Human Clinical Study Of Pl-8177

Feb 5 (Reuters) - Palatin Technologies Inc:

* PALATIN TECHNOLOGIES, INC. INITIATES SUBJECT DOSING IN FIRST-IN-HUMAN CLINICAL STUDY OF PL-8177, AN INVESTIGATIONAL MELANOCORTIN RECEPTOR 1 AGONIST

* PALATIN TECHNOLOGIES INC - TOP LINE DATA FROM STUDY OF PL-8177 IS CURRENTLY EXPECTED IN Q3 OF 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below